A characteristic feature of myasthenia gravis (MG) is the fluctuating weakness of the muscles. MG is an autoimmune neuromuscular junction disorder mediated by autoantibodies against nicotinic acetylcholine receptor and muscle-specific tyrosine kinase. If the commercially available acetylcholine receptor and muscle-specific tyrosine kinase antibody test is negative, MG patients are termed as having double-seronegative MG. Although the clinical phenotype is not yet defined, antibodies for lipoprotein receptor-related protein 4 and agrin, involved in clustering of acetylcholine receptors within the postsynaptic membrane and in structural maintenance of the neuromuscular synapse, have been found. The updated 2014 Guidelines in Japan state that the management of MG should be individualized, and earlier aggressive treatment using steroid pulse, plasma exchange and intravenous immunoglobulin therapy, before long-term steroid therapy, should be used in order to minimize manifestation, with fewer adverse effects achieved by co-administering immunosuppressants. In 2016, thymectomy was shown to be efficacious in non-thymomatous MG in a single-arm randomized clinical trial. The continuous update and modification in MG management makes it difficult for the general neurologist to decide on a treatment strategy. The present review aims to improve the understanding of current MG diagnosis, specific immunotherapy and clinical management tips, not only for the general neurologist, but also for other medical staff.
Introduction
Myasthenia gravis (MG) is characterized by daily fluctuating, painless skeletal muscle weakness, which affects the ocular, bulbar, neck, respiratory and limb muscles, and which worsens in the evening; patients complain of easy fatigability. Because it is an antibody-mediated autoimmune disorder of the neuromuscular junction, immune intervention is the choice for maintenance treatment. The management strategy varies in different countries, but steroids and immunosuppressants have long been used with cholinesterase inhibitors. The mortality rate has decreased from 30% in the 1950s to 10% in 2000, but the complete remission rate has remained the same. Because of the requirement for long-term immunosuppression, which has been achieved with a moderate-to-high dose of steroid, supportive and preventive therapies for hypertension, osteoporosis, aseptic bone necrosis, infectious disease, diabetes mellitus, gastric ulcer, depression, and steroid psychosis are mandatory, and steroid-sparing agents need to be introduced as early as possible.
There have been a number of publications on guidelines or consensus reports on MG diagnosis and treatment, but the approaches and practices differ according to the authors' experience and country, because the definitions and subgroupings vary. In the present review, we will focus on the new Japanese clinical guidelines for MG of 2014, 1 and the expert opinions derived from three decades of treatment of 400 MG patients at Juntendo University Hospital, Tokyo, Japan, to provide a guide for general practitioners and caregivers.
Epidemiology
Myasthenia gravis is an autoimmune disorder affecting approximately 15 people per 100 000. 2 Approximately 10% of patients are children and adolescents. Female preponderance in early-onset MG (EOMG) has been reported, and there has been an increase in the prevalence and incidence of late-onset MG (LOMG) worldwide. In addition to using the profile of autoantibodies, MG can be classified according to the location of the affected muscles (ocular vs generalized), the age of symptom onset and the nature of the thymic pathology. 3 
Autoantibody and pathophysiology
The neuromuscular junction has no blood-nerve barrier, so antibodies easily attack the components. The most common antibody found in patients with MG is directed against the acetylcholine receptor (AChR), and is found in 85% of generalized MG patients and 50% of ocular MG patients. Different types of antibodies exist; the isotype of the AChR antibody is immunoglobulin G (IgG)1 or IgG3, and therefore, antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity are the main pathomechanisms, which results in the destruction or competitive reversible blocking of receptors. Approximately 70% of cases that are seronegative for AChR are indeed positive when assessed by a cell-based assay. 4 Of the 15% of patients that are not positive for AChR antibody, up to 50% have antibodies to muscle-specific kinase (MuSK). 5, 6 The frequency of MuSK-MG differs across populations, with a higher prevalence in European than in Asian countries. MuSK is a protein that is expressed in the postsynaptic muscle membrane, and is functionally linked to AChR and is necessary for maintaining AChR function. MG-associated MuSK antibodies are of the non-complement-binding IgG4 subclass, and MuSK-MG has unique clinical features, such as prominent bulbar weakness, muscle atrophy and relative sparing of the ocular muscles. 7 However, there are an increasing number of reports describing circulating antibodies to other endplate proteins in MG. These include the low-density lipoprotein receptor-related protein-4; 8,9 the antibodies bind to this membrane protein in vivo, blocking the agrin-low-density lipoprotein receptorrelated protein-4 interaction, and thereby also inhibiting AChR clustering in the membrane. Other proteins targeted by MG-associated antibodies are agrin 10 (essential for AChR function), rapsyn 11 and most recently, cortactin. 12 Neoplastic epithelial cells variably express striational antigen epitopes, including titin (which maintains the flexibility of the muscle cell structure) and ryanodine (a sarcoplasmic reticulum calcium channel that mediates contraction of the muscle cell). Antibodies to these two proteins occur in some patients with AChR-associated MG with thymoma, and this is considered a marker for paraneoplastic MG. MG subgroups with different autoantibodies, with or without thymoma, have been found to have relatively distinct clinical features and to respond differently to standard immunotherapy.
Classification
Autoimmune MG can be subdivided based on the profile of serum autoantibodies, the age of onset, the presence or absence of thymic abnormality and the distribution of clinical weakness. Individual symptoms include only affected eyes (ptosis, double vision), termed the ocular type; whereas if general muscle involvement predominates, it is termed generalized MG. Generalized MG with early onset is termed EOMG (<50 years), whereas generalized MG with a late onset is termed LOMG (≥50 years). Approximately 70% of EOMG is associated with lymphofollicular hyperplasia of the thymus, whereas LOMG is characterized by age-dependent involution of the thymus. In contrast, 10-15% of all patients The goal in myasthenia gravis (MG) treatment is minimal manifestations (MM) with oral prednisolone (PSL) of 5 mg/day or below, with or without immunosuppressant, and treatment strategies should strive to attain this level as rapidly as possible. In crisis, plasma exchange therapy or intravenous immunoglobulin (IVIg) therapy will be applied. AZA, azathioprine; CEI, cholinesterase inhibitor; CyA, cyclosporine A; MMF, mycophenolate mofetil; PLEX, plasma exchange; PSL, prednisolone; Tac, tacrolimus.
have thymoma, and approximately 30% of thymoma patients develop MG, termed thymoma-associated MG (TAMG); 3 these patients are more likely to have bulbar symptoms and crisis. Pure red aplasia and neuromyotonia are also associated with TAMG. A computed tomography scan is considered the main screening tool for thymoma, with high sensitivity and specificity. Contrast medium is not mandatory, but follow-up computed tomography is required to avoid misdiagnosis of thymic hyperplasia and occult thymoma.
The severity at the first diagnosis is assessed using the Myasthenia Gravis Foundation of America Clinical Classification, and the Quantitative MG score is utilized for determining disease severity. 1 
Symptoms
Weakness in MG arises in the facial (myopathic face), ocular (ptosis and enhanced ptosis) and extraocular (double vision), bulbar, limb, and axial muscles. Patients complain about increased weakness and fatigue during exercise and repetitive muscle use, with at least partial restoration of strength after periods of rest. MG can present with head-drop, particularly in MuSK-positive cases and in the elderly. 13, 14 Identifying any diurnal variation in symptoms can be important: patients with neuromuscular junction illness, such as MG, might notice weakness at the end of the day or after exertion, but regain normal strength by the next morning. 15 Non-motor symptoms, such as anxiety, depression, insomnia and overactive bladder, are sometimes difficult to manage as a result of cholinergic-anticholinergic drug interactions. Melatonin receptor agonist is used for insomnia, targeting the suprachiasmatic nucleus, the body's "master clock" that regulates circadian (24-h) rhythms, including the sleepwake cycle. Suvorexant is a selective, dual orexin receptor antagonist that is recommended for generalized MG with insomnia, rather than benzodiazepines. For overactive bladder, mirabegron is a choice, working through activation of the b 3 -adrenoceptor, and promoting smooth muscle relaxation through a 1 -adrenergic receptor blockade.
Diagnosis
A diagnosis of MG is confirmed by the presence of antibodies against AChR, MuSK or other aforementioned autoantibodies in individuals with symptoms consistent with the disease. Neurophysiological tests become helpful in diagnosing symptomatic patients with undetectable antibodies. Repetitive peripheral nerve stimulation, at a rate of 2-3 Hz, shows a characteristic decremental response (>10%), while single-fiber electromyography shows increased jitter. An edrophonium chloride (Tensilon) test shows recovery of the weakness after intravenous injection; however, bradycardia and/or hypotension can sometimes occur. 16 To rule out the conversion reaction, a placebo injection using saline solution is recommended before injecting the active drug. Other neurological diseases, such as congenital myasthenic syndrome, myopathies (e.g. oculopharyngeal muscular dystrophy, mitochondrial progressive external ophthalmoplegia), steroid and inflammatory myopathies, motor neuron disease, Eaton-Lambert syndrome, multiple sclerosis (weakness with chronic fatigue or subacute/acute brainstem or spinal cord motor involvement), variants of Guillain-Barr e syndrome (e.g. Miller-Fisher syndrome), organophosphate toxicity, botulism, black widow spider venom, stroke, and hypokalemia, should be excluded.
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Thymectomy
The MGTX study is a multicenter, single-blind, randomized study that compares thymectomy to no thymectomy in non-thymomatous MG patients. That study showed that, in non-thymomatous generalized AChR antibody-positive adult MG patients with <5 years of disease history, thymectomy reduced corticosteroid requirements. 18 Some patients found that it was not clear whether taking long-term lowdose corticosteroids or azathioprine was preferable. 19 The absolute indication for thymectomy is the presence of a thymoma, but in the elderly, it might be necessary to consider the effect on their quality of life status. For patients aged <50 years, with nonthymomatous, generalized AChR antibody-associated MG, we recommend thymectomy as soon as the patient's degree of weakness is sufficiently controlled to permit surgery by immunotherapy. For patients aged <50 years, with non-thymomatous, generalized MG and no detectable AChR or MuSK antibodies (i.e. seronegative MG), the indication for thymectomy is determined case-by-case. For patients with non-thymomatous, generalized MuSK antibodyassociated MG, and for most patients aged ≥60 years, we suggest avoiding thymectomy. When deciding on thymectomy, there are no direct controlled comparisons between a less-invasive thymectomy and more aggressive approaches for non-thymomatous MG. It is ideal to resect all mediastinal tissue that could contain gross or microscopic thymus tissue. Ectopic thymic tissue is not uncommon in patients with non-thymomatous MG, and the clinical outcome of MG is significantly affected by its presence. 20 MGTX used extended trans-sternal thymectomy, a technique that resects 85-95% of thymic tissue. 18 
Therapy
In the international consensus for managing MG, minimal manifestation status or better was recommended as the treatment goal. 21 The minimal manifestation status refers to the absence of symptoms of functional limitations related to MG, but the presence of some weakness on examination of some muscles. 22 Treatment strategies for MG can be divided into: (i) symptomatic treatments with cholinesterase inhibitors facilitating neuromuscular transmission;
(ii) immunotherapeutic treatment strategies (glucocorticosteroid; glucocorticosteroid plus azathioprine, cyclosporine A, methotrexate, mycophenolate mofetil; mycophenolate mofetil or tacrolimus for basic therapy; cyclophosphamide or rituximab for escalation therapy) for maintenance therapy; and (iii) antibodydepleting treatments (intravenous immunoglobulin [IVIg] , plasmapheresis or immune-absorption) for acute therapeutic intervention. 23 
Symptomatic therapy
The first-line symptomatic treatment for AChR antibody-positive patients is the cholinesterase inhibitor, pyridostigmine bromide (Mestinon). Cholinesterase inhibitors provide temporary relief of symptoms, but do not induce complete or sustained relief of MG symptoms in most patients, and do not affect disease progression. They might be sufficient for management of patients with non-progressive mild or purely ocular disease, and might allow reduction of the dosage of immune-modulating agents. These agents have a rapid onset of action (15-30 min), with peak action at approximately 2 h, and their effects last for 3-4 h. The maximal dose and frequency is usually 120 mg every 4 h while awake. Those who have trouble chewing or mild dysphagia might benefit from taking a dose 30 min before a meal. The most bothersome muscarinic side-effects include abdominal cramping and diarrhea; others are increased salivation and bronchial secretions, nausea, sweating, and bradycardia. Nicotinic side-effects are also frequent, and include fasciculation and muscle cramping. Oral ambenonium chloride can be used instead of oral pyridostigmine bromide in cases of bromide intolerance, with gastrointestinal side-effects. Prominent diarrhea can be reduced by the addition of loperamide (Imodium) or diphenoxylate hydrochlorideatropine sulfate (Lomotil), with or without other anticholinergic drugs.
17 Doses of pyridostigmine rarely exceed 450-600 mg/day, as a higher dose could result in increased muscle weakness and precipitate a cholinergic crisis. 24 Patients with MuSK-MG might not respond to pyridostigmine, and higher doses could lead to increased weakness, thought to be a result of desensitization of AChR. 25 Naphazoline, a primarily a2-agonist, selectively increases the tone of the Muller muscle without mydriasis, and is clinically used to treat congestion and to improve ptosis related to MG in the form of topical eye drops. 26 
Immunotherapeutic treatment
Glucocorticosteroids are the fastest-acting (approximately 4-8 weeks) immunomodulating medications available for MG. 27 Although no randomized controlled trial has been carried out, prednisolone and prednisone are usually started at high doses, such as 0.75-1 mg/kg/day, and are titrated until optimization of symptoms is achieved. However, an initial transient deterioration occurs in up to 50% of patients with MG when high-dose glucocorticoids are started, usually occurring 2-7 days after the initiation and lasting approximately 5 or 6 days. Therefore, in patients at risk of crisis, such as those with a generalized bulbar type, treatment should start with immunosuppressants, such as tacrolimus, or 10-20 mg/day of glucocorticoids, with a dosage increase of 5 mg/week. Treatment initiation with high doses or steroid pulse therapy is recommended for use only in hospitalized patients who are receiving concurrent plasmapheresis or IVIg. 17 In the Japanese Guidelines of 2014, it was recommended that "Highdose oral steroids, utilizing dose escalation and deescalation, are effective against MG, but long-term use of oral steroids above a certain dosage level is known to involve a number of problems. Therefore, this approach is now being reconsidered, and highdose oral steroids require careful consideration, given the other treatment options available." The dose of prednisolone should then be gradually tapered, until the lowest dose required to maintain remission is found. In such cases, there should be awareness of the possibility of steroid myopathy. Less than 30 mg/day of prednisolone should be used, and the use of fluoride steroid should be avoided. Alternate-day dosing has also been suggested to minimize side-effects, and is utilized in the neuroimmunological community. In cases with an estimated therapy duration of longer than 3 months, with a dosage of 7.5 mg prednisoloneequivalent, patients should be treated with calcium (1000-1500 mg/day) and vitamin D (400-800 IE/ day), with bisphosphonates, to prevent osteoporosis. Prophylactic use of stomach protection using protonpump inhibitors or H 2 blockers depends on patients.
Effective use of chronic immunomodulation by immunosuppressants, such as tacrolimus (3 mg/day, with a trough of approximately 4-7 ng/mL), and cyclosporine A (3-5 mg/kg/day, trough 200 ng/mL) can spare patients from steroid use in MG. 28, 29 Both these calcineurin inhibitors suppress interleukin-2 production in T cells and inhibit the glucocorticoid transporter function of P-glycoprotein. In MG, the early stages of disease and thymoma-associated MG are responsive to treatment with calcineurin inhibitors. 30 The long-term risk of malignancy is not established, but there are reports of an increased occurrence of malignancy in patients with MG and other autoimmune diseases receiving immunosuppression; 31, 32 therefore, the minimum doses of immunosuppressant medications required to maintain control of the disease should be used. Azathioprine and MMF are off-label in Japan, but are used as first-line medication abroad. Azathioprine, at 2-3 mg/kg, is used in combination with steroids, but the maximum effect is seen only after more than 6 months. Clinicians should also be aware of relative contraindications for the use of glucocorticoids (such as diabetes or advanced age, osteoporosis), tacrolimus (diabetes), liver disease (precluding azathioprine use), hypertension and renal disease (precluding cyclosporine use), or leukopenia (problematic for both azathioprine and mycophenolate) 17 or methotrexate (hepatotoxicity, ulcerative stomatitis, leucopenia, anemia, infections).
Although not licensed in Japan, rituximab is a chimeric IgG1 monoclonal antibody that binds to transmembrane antigen CD20 and leads to B-lymphocyte depletion. It has been successfully applied for the treatment of refractory MG in multiple small uncontrolled trials and case reports. 33, 34 Rituximab has also been particularly beneficial in the treatment of MuSK antibody-positive MG. 35 As with all drugs, this drug should be used at the lowest dose possible; potential adverse effects, such as progressive multifocal leukoencephalopathy, posterior reversible encephalopathy syndrome and hepatitis B virus reactivation, and complications of any treatment, should be known, monitored, prevented and treated. 36 
Antibody-depleting treatments, IVIg and plasma exchange
These treatments are used for acute severe exacerbations in generalized MG, to optimize strength before surgery, for rapid short-term immunomodulating therapy or as an adjuvant to other immunotherapeutic medications in patients with refractory MG. Periodically, it can be used to maintain remission in patients with MG that is not well controlled, despite the use of chronic immune-modulating drugs. IVIg is pooled immunoglobulin obtained from thousands of donors. The mechanism of action for IVIg in MG is uncertain, but it can be utilized safely in children and elderly individuals, and even in pregnant women. The side-effects of IVIg are most commonly mild and transient, and are related to the infusion rate (a rate of 0.03 mL/kg/min should not be exceeded). 37, 38 These side-effects include headache, chills, dizziness and fluid retention. Other uncommon complications include aseptic meningitis, acute renal failure, thrombotic events and anaphylaxis. The half-life of IgG is 3 weeks, and live vaccines should be administered only after 3 months have passed since IVIg treatment.
Plasma exchange (PLEX) can have a faster onset of action, sometimes within 24 h, and is the treatment of choice in MG crisis. PLEX is not to be used in patients with infection. The beneficial clinical effect of plasmapheresis is usually seen within days, but the benefit typically lasts just 3-6 weeks. In Japan, we have options for PLEX for MG; that is, immunoabsorption plasma exchange with a tryptophan column, double-filtration plasma exchange and simple plasma exchange. Immunoabsorption plasma exchange is convenient and allows patients to be treated at outpatient clinics, through a peripheral vein. However, angiotensin-converting enzyme inhibitors must be withheld 24-72 h before treatment and until treatment is complete, because immunoabsorption plasma exchange increases bradykinin levels, and there is an increased chance of inducing shock. For MG with MuSK antibody or seronegative MG, double-filtration plasma exchange or PLEX is recommended.
Crisis
Abrupt cessation of immunosuppression, especially in a clinically unstable situation, can trigger deterioration of myasthenic symptoms and precipitate a myasthenic crisis. 39, 40 Although many patients with MG are controlled with cholinesterase inhibitor medications, acute myasthenic crisis affects 15-20% of patients with myasthenia, and carries a 3-8% mortality rate. IVIg and PLEX are specific immunosuppressive treatments with a rapid effect occurring after 2-5 days, and either treatment should be given. A myasthenic crisis can be precipitated by a number of factors; however, infection is responsible for 40-70% of crisis episodes. 2, 41 Initial antibiotic therapy is often chosen in the emergency department, which can occur before a consultation with a neurologist or infectious disease specialist. For this reason, it is increasingly important for the emergency medicine physician to be aware of the potential that antibiotic medication administration might precipitate a myasthenic crisis.
In reviewing the literature, myasthenia symptoms, such as dyspnea, muscle weakness and fatigue, unfold within the first 24-48 h after initiation of a new therapy and resolve shortly after drug cessation, within approximately 8 h to few days. 42 Many patients present with a complicated clinical picture, where it is difficult to determine whether acute shortness of breath is caused by a myasthenic crisis or by an underlying illness, or sometimes by a cholinergic crisis that is paradoxical to the weakening with anticholinesterase medications. The size of the pupil should be observed (miosis in a cholinergic crisis) and if a differential diagnosis is not obtained, the patient should immediately be intubated and cholinesterase inhibitor treatment stopped, 17 and if it is as a result of cholinergic crisis, the patient should be treated with atropine sulfate (1-2 mg i.v.). When initiating new antibiotic medications in a patient with a history of MG, it might be wise to observe the patient for the first 1-2 days of therapy to determine the safety of the medication. If any symptoms of MG exacerbation are noted in a patient receiving any antibiotics, it is recommended that the agent be stopped, and an alternative antibiotic used, if feasible. 16 Fluoroquinolone, ketolides (particularly telithromycin), and aminoglycoside antibiotics, beta-blockers, procainamide, quinidine, quinine and magnesium worsen the disease and are contraindicated. 43 Stress from myasthenia or myasthenic crisis can trigger Takotsubo (broken heart) syndrome (TTS). The age at occurrence of TTS in myasthenia patients ranges from 42 to 83 years, with a striking female preponderance. The classic type of TTS prevails. As mortality from TTS due to a myasthenic crisis is high, TTS must be diagnosed as early as possible, to take all possible measures to reduce stress and to initiate appropriate cardiac treatment. TTS as a result of a myasthenic crisis can be circumvented by avoiding stress, which can be achieved by careful management of these patients. In cases of acute cardiac manifestations in patients with myasthenia, TTS must be excluded. 44 
Juvenile MG
Juvenile MG, a subtype of early-onset disease, has a high frequency in east Asia, in which up to 50% of all cases have disease onset before the age of 15 years, many of them with ocular symptoms only. 45, 46 Approximately 50% of the individuals are seronegative for AChR antibody. In patients aged <3 years, ptosis and double vision cause amblyopia ex anopsia. Steroid with pyridostigmine is a basic treatment for this condition. Poor school performance is common among patients with juvenile MG; therefore, doctors should share the information with the schoolteacher.
Pregnancy
The first trimester and first few months postpartum are the periods of risk of MG exacerbation. Mothers with MG should always give birth at hospitals that are experienced in respiratory support treatment for newborn babies. Cesarean section is not recommended as a routine procedure, and should only be used in prolonged birth or breech delivery.
During the pregnancy, treatment with a steroid at a level of <20 mg/day is permitted. Steroids have a short half-life: hydrocortisone, prednisolone and methyl prednisolone are metabolized by 11-betahydroxysteroid dehydrogenase type 2. Transient neonatal MG develops in 10-20% of infants born to myasthenic mothers as a result of transplacental passage of anti-acetylcholine receptor antibodies. For breast-feeding mothers, use of 30 mg/day of prednisolone is acceptable. According to the FDA, pregnancy and lactation labeling rule risk is as follows: tacrolimus and cyclosporine A are categorized as C (risk not ruled out), azathioprine cyclophosphamide and mycophenolate mofetil as D (positive evidence of risk), and methotrexate as X (contraindication).
Rehabilitation
Exercise is not necessarily a contraindication in MG, and rehabilitation can be safely carried out before and after thymectomy, reducing operative risks and decreasing recovery time. 47 No controlled studies of MG training programs have been published.
Tips
Comorbidity
Patients with early-onset and ocular subgroups of MG have an increased frequency of organ-specific and general autoimmune disorders, especially thyroiditis, rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis and neuromyelitis optica. We have observed pure red cell aplasia, alopecia areata, sweet taste loss, muscle cramp and limbic encephalitis in TAMG.
In TAMG, anti-Kv1.4 antibodies are possible markers for bulbar involvement, myasthenic crisis, myocarditis and QT prolongation on electrocardiogram. 48, 49 
Steroid myopathy
Patients with glucocorticoid myopathy typically present with gradual onset of proximal muscle weakness, followed by atrophy of proximal muscle groups. Myalgias and muscle tenderness do not occur. 50 Prolonged administration of prednisolone at a dose of more than 40 mg/day poses a risk. The risk is greater with the use of fluorinated steroids, such as dexamethasone. Usually, the hand and facial muscles are spared. Serum levels of muscle-associated enzymes, such as creatine kinase, lactate dehydrogenase and aldose, are usually normal. Treatment involves reducing the steroid dose to below a threshold level, or its discontinuation.
Steroid withdrawal symptoms
To avoid adverse effects of long-term steroid use, the drug should be tapered as soon as the disease is under control. Tapering must be done carefully to avoid both recurrence of the underlying disease and possible cortisol deficiency resulting from hypothalamic-pituitaryadrenal axis suppression. The following non-specific symptoms are observed: weakness, fatigue, decreased appetite, weight loss, nausea, vomiting, diarrhea, abdominal pain and arthralgia. Adrenal insufficiency should be suspected, and supplementation with corticosteroid medication during periods of stress (such as surgery, infection, delivery), even up to a year after stopping corticosteroid therapy, should be given.
New oncotherapy and secondary MG
There has been recent interest in disinhibition of the natural antitumor immune response by targeting immune checkpoints, such as cytotoxic T lymphocyte-associated antigen-4 (CTLA-4), and programmed death-1 (PD-1). Ipilimumab for CTLA-4 and nivolumab or pembrolizumab for PD-1 have shown a unique spectrum of toxic effects in isolated cases of MG. 51 PD-1 regulates the immune response in peripheral tissues and suppresses autoimmune phenomena by promoting tolerance. Pembrolizumab, a humanized monoclonal IgG4-kappa antibody against PD-1, has recently been approved for treatment of metastatic malignant melanoma; significant clinical responses have also been observed in other malignancies, including renal cell carcinoma, non-small cell lung cancer, bladder cancer and Hodgkin lymphoma, but new onset or exacerbated MG have been reported. 52, 53 Vaccination Inactivated vaccines (e.g. pneumococcal and intramuscular influenza vaccines) are generally considered safe in adults and children with immunocompromising conditions or who are taking immunosuppressive drugs. Although the immunosuppressive effects of steroid treatments vary, the majority of clinicians consider a dose equivalent to either ≥2 mg/kg of bodyweight or ≥20 mg/day of prednisone or equivalent for persons who weigh >10 kg, when administered for ≥14 days, as sufficiently immunosuppressive to raise concern about the safety of vaccination with live-virus vaccines. 54 Corticosteroids used in greater than physiological doses can also reduce the immune response to vaccines. Vaccination providers should defer live-virus vaccination for at least 1 month after discontinuation of high-dose systemically absorbed corticosteroid therapy that was administered for >14 days. Until additional information becomes available, avoidance of live, attenuated vaccines during intermittent or low-dose chemotherapy or other immunosuppressive therapy is prudent, unless the benefit of vaccination outweighs the hypothetical increased risk of an adverse reaction after vaccination. 55 
Conclusion
Steroid therapy is still the least expensive option, and is utilized as the first choice in maintenance therapy for MG. However, chronic use of a steroid and its adverse effects decrease patients' quality of life and complete remission was observed in just 3.9% in a Japanese registry study in 2012. Therefore, the benefits and drawbacks of currently used immune-modulating medicine and approaches should be known, and tailored and more aggressive treatment with an immunosuppressant should be pursued.
